title: Effect of race/ethnicity on the efficacy of warfarin: potential implications for prevention of stroke in patients with atrial fibrillation.
abstract: Atrial fibrillation (AF) is the most common sustained arrhythmia seen in clinical practice. It affects approximately 6% of persons over 65 years of age and is independently associated with a 4- to 5-fold higher risk of ischaemic stroke and a 2-fold higher risk of death. Randomized controlled trials have shown that treatment with adjusted-dose oral vitamin K antagonists (primarily warfarin with a target international normalized ratio [INR] of 2.0-3.0) reduces the relative risk of ischaemic stroke by two-thirds (an approximately 3% reduction in annual absolute risk), but is associated with a 0.2% excess annual absolute risk of intracranial haemorrhage (ICH). However, in 'real world' studies, the risk reductions in ischaemic stroke with warfarin have been significantly lower (25-50% relative risk reduction) than in selected trial samples. Moreover, more than 90% of patients enrolled in the sentinel trials were White/European. This raises the question of whether the beneficial results of warfarin can be extrapolated to persons of colour. Important differences in stroke risk profile and responsiveness to warfarin exist across racial/ethnic groups, such that one cannot assume a priori that there is a net benefit of warfarin therapy for AF patients of all racial/ethnic groups.Among patients with ischaemic stroke, AF is more likely to be implicated as the cause of stroke in the White population than in other racial/ethnic groups. Furthermore, AF may be a stronger predictor of ischaemic stroke among the White population than in Black or Hispanic/Latino populations. Approximately one-third of strokes in AF patients are noncardioembolic. Warfarin has been shown to be ineffective in preventing recurrent noncardioembolic strokes. Many persons of colour with AF have other risk factors that predispose them to noncardioembolic stroke, which may partially explain why warfarin has been reported to be less efficacious in preventing strokes in non-White patients with AF, even after adjustment for co-morbidities and anticoagulation monitoring. Notably, the background incidence of ICH is higher in Black, Hispanic and Asian patients than in White patients. Any greater than expected increases in bleeding secondary to anticoagulation may potentially offset any benefit gained from cardioembolic stroke reduction, although this has not been fully resolved.Finally, there are racial/ethnic differences in the prevalence of certain polymorphisms in genes that influence warfarin pharmacokinetics and pharmacodynamics (e.g. cytochrome P450 2C9 and vitamin K epoxide reductase). The Asian population generally appear to require the lowest daily dose of warfarin to maintain a given INR target, with the White population requiring an intermediate daily dose and the Black population requiring the highest daily dose. These differences must be taken into account when administering warfarin in order to minimize the risk of under- or over-anticoagulation.In summary, warfarin is highly effective in preventing ischaemic strokes in White patients with AF at a modestly higher risk of ICH. Whether the same net clinical benefit extends to persons of colour is unproven. Given the rapidly changing demographic nationally and internationally, additional research is needed to resolve this important question.
authors.affiliation: Department of Cardiology, Kaiser Permanente Medical Center, Los Angeles, California 90027, USA. albert.y-j.shen@kp.org
authors.forename: Albert Yuh-Jer
authors.initials: AY
authors.lastname: Shen
authors.forename: Wansu
authors.initials: W
authors.lastname: Chen
authors.forename: Janis F
authors.initials: JF
authors.lastname: Yao
authors.forename: Somjot S
authors.initials: SS
authors.lastname: Brar
authors.forename: Xunzhang
authors.initials: X
authors.lastname: Wang
authors.forename: Alan S
authors.initials: AS
authors.lastname: Go
mesh_terms: D000925:Anticoagulants / Q000008:administration & dosage / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000208:ethnology* / Q000517:prevention & control*; D006801:Humans; D019934:International Normalized Ratio; D010597:Pharmacogenetics; D020521:Stroke / Q000208:ethnology* / Q000517:prevention & control*; D014859:Warfarin / Q000008:administration & dosage / Q000627:therapeutic use*
chemical_list: D000925:Anticoagulants; D014859:Warfarin
references.citation: N Engl J Med. 1992 Mar 12;326(11):733-6
references.pmid: 1738378
references.citation: JAMA. 2002 Apr 3;287(13):1690-8
references.pmid: 11926893
references.citation: J Am Coll Cardiol. 2006 Aug 15;48(4):854-906
references.pmid: 16904574
references.citation: Br J Clin Pharmacol. 2005 May;59(5):582-7
references.pmid: 15842557
references.citation: Stroke. 2001 Dec 1;32(12):2828-32
references.pmid: 11739981
references.citation: J Thromb Thrombolysis. 2003 Dec;16(3):155-61
references.pmid: 15087601
references.citation: Adv Drug Deliv Rev. 2002 Nov 18;54(10):1257-70
references.pmid: 12406644
references.citation: Stroke. 2008 Oct;39(10):2736-43
references.pmid: 18635860
references.citation: Stroke. 1991 Mar;22(3):299-304
references.pmid: 2003299
references.citation: Thromb Haemost. 2004 Jan;91(1):87-94
references.pmid: 14691573
references.citation: Med Clin North Am. 2005 Jul;89(4):739-52, vii
references.pmid: 15925647
references.citation: PLoS Med. 2005 Oct;2(10):e312
references.pmid: 16201835
references.citation: Am J Epidemiol. 2004 Aug 15;160(4):376-83
references.pmid: 15286023
references.citation: Cochrane Database Syst Rev. 2003;(1):CD000248
references.pmid: 12535394
references.citation: Lancet Neurol. 2007 Feb;6(2):115-24
references.pmid: 17239798
references.citation: Stroke. 2000 Apr;31(4):817-21
references.pmid: 10753981
references.citation: Am J Epidemiol. 2002 May 1;155(9):819-26
references.pmid: 11978585
references.citation: Stroke. 2006 Jun;37(6):1374-8
references.pmid: 16690900
references.citation: J Am Coll Cardiol. 2007 Jul 24;50(4):309-15
references.pmid: 17659197
references.citation: Stroke. 2004 Jul;35(7):1562-7
references.pmid: 15192251
references.citation: Ann Intern Med. 2004 Nov 16;141(10):745-52
references.pmid: 15545674
references.citation: Stroke. 2002 Dec;33(12):2789-93
references.pmid: 12468771
references.citation: Arch Intern Med. 1995 Mar 13;155(5):469-73
references.pmid: 7864703
references.citation: Stroke. 2003 Sep;34(9):2091-6
references.pmid: 12907817
references.citation: Neuroepidemiology. 2005;25(1):26-31
references.pmid: 15855802
references.citation: JAMA. 2002 Nov 20;288(19):2441-8
references.pmid: 12435257
references.citation: Curr Hematol Rep. 2002 Sep;1(1):41-9
references.pmid: 12901124
references.citation: Ann Intern Med. 1994 Jun 1;120(11):897-902
references.pmid: 8172435
references.citation: Pharmacogenetics. 1994 Feb;4(1):39-42
references.pmid: 8004131
references.citation: Pharmacogenomics J. 2005;5(4):262-70
references.pmid: 15883587
references.citation: Stroke. 2000 Apr;31(4):822-7
references.pmid: 10753982
references.citation: Ann Intern Med. 2007 Jun 19;146(12):857-67
references.pmid: 17577005
references.citation: Am Heart J. 1983 Aug;106(2):389-96
references.pmid: 6869222
references.citation: Intern Med. 2001 Dec;40(12):1183-8
references.pmid: 11813841
references.citation: Am J Cardiol. 2004 Aug 15;94(4):500-4
references.pmid: 15325940
references.citation: Circulation. 2007 Nov 27;116(22):2563-70
references.pmid: 17989110
references.citation: Stroke. 1996 Oct;27(10):1760-4
references.pmid: 8841325
references.citation: Ann Pharmacother. 2005 Jun;39(6):1008-12
references.pmid: 15855242
references.citation: JAMA. 2003 Nov 26;290(20):2685-92
references.pmid: 14645310
references.citation: Pharmacogenet Genomics. 2006 Feb;16(2):101-10
references.pmid: 16424822
references.citation: Chest. 2007 Oct;132(4):1253-8
references.pmid: 17890461
references.citation: Ethn Dis. 1997 Winter;7(1):27-33
references.pmid: 9253553
references.citation: Lancet. 2006 Jun 10;367(9526):1903-12
references.pmid: 16765759
references.citation: Lancet. 1999 Feb 27;353(9154):717-9
references.pmid: 10073515
references.citation: Drug Saf. 2003;26(8):585-8
references.pmid: 12825970
references.citation: Circulation. 2003 Aug 12;108(6):711-6
references.pmid: 12885749
references.citation: Am J Cardiol. 2001 Jan 15;87(2):168-71
references.pmid: 11152833
references.citation: Br J Haematol. 1999 Oct;107(1):207-9
references.pmid: 10520043
references.citation: Stroke. 1995 Feb;26(2):245-8
references.pmid: 7831696
references.citation: Circulation. 2006 Jul 11;114(2):119-25
references.pmid: 16818816
references.citation: Chest. 2004 Sep;126(3 Suppl):287S-310S
references.pmid: 15383476
references.citation: Ann Thorac Surg. 1996 Feb;61(2):755-9
references.pmid: 8572814
references.citation: Blood. 2005 Jan 15;105(2):645-9
references.pmid: 15358623
references.citation: Cerebrovasc Dis. 2000 Jan-Feb;10(1):39-43
references.pmid: 10629345
references.citation: Stroke. 2001 Aug;32(8):1725-31
references.pmid: 11486097
references.citation: Chest. 2004 Sep;126(3 Suppl):204S-233S
references.pmid: 15383473
references.citation: Neurology. 1996 Aug;47(2):405-8
references.pmid: 8757012
references.citation: Stroke. 2001 Aug;32(8):1732-8
references.pmid: 11486098
references.citation: Arch Intern Med. 1994 Jul 11;154(13):1449-57
references.pmid: 8018000
references.citation: Blood. 2005 Jul 1;106(1):135-40
references.pmid: 15790782
references.citation: JAMA. 2001 May 9;285(18):2370-5
references.pmid: 11343485
references.citation: N Engl J Med. 2005 Jun 2;352(22):2285-93
references.pmid: 15930419
references.citation: Neuroepidemiology. 1997;16(5):224-33
references.pmid: 9346342
references.citation: Clin Pharmacol Ther. 2008 Feb;83(2):312-21
references.pmid: 17653141
references.citation: Am J Cardiol. 2003 Dec 15;92(12):1476-9
references.pmid: 14675592
references.citation: Stroke. 1991 Aug;22(8):983-8
references.pmid: 1866765
references.citation: Stroke. 2005 Feb;36(2):374-86
references.pmid: 15637317
references.citation: Stroke. 2006 Apr;37(4):1070-4
references.pmid: 16528001
references.citation: Circulation. 2006 Feb 14;113(6):e85-151
references.pmid: 16407573
references.citation: Ann Pharmacother. 2006 Jun;40(6):1024-9
references.pmid: 16735649
references.citation: Stroke. 1998 Jan;29(1):29-33
references.pmid: 9445324
references.citation: Genet Med. 2005 Feb;7(2):97-104
references.pmid: 15714076
references.citation: Int J Cardiol. 2005 Dec 7;105(3):283-7
references.pmid: 16274769
references.citation: Hum Mol Genet. 2005 Jul 1;14(13):1745-51
references.pmid: 15888487
references.citation: Stroke. 2003 Nov;34(11):2671-5
references.pmid: 14576374
references.citation: Circulation. 2005 Sep 20;112(12):1687-91
references.pmid: 16157766
references.citation: Biochem Biophys Res Commun. 1999 Jan 27;254(3):628-31
references.pmid: 9920790
references.citation: Stroke. 1996 Oct;27(10):1765-9
references.pmid: 8841326
references.citation: Clin Pharmacol Ther. 2006 Oct;80(4):346-55
references.pmid: 17015052
references.citation: Thromb Res. 2007;120(1):1-10
references.pmid: 17161452
references.citation: Circulation. 2007 Feb 6;115(5):e69-171
references.pmid: 17194875
references.citation: Arch Intern Med. 1995 Jun 26;155(12):1319-24
references.pmid: 7778964
references.citation: J Thromb Haemost. 2006 Sep;4(9):1944-9
references.pmid: 16824187
references.citation: PLoS Med. 2006 Apr;3(4):e205; author reply 210
references.pmid: 16626259
references.citation: Ann Pharmacother. 2002 Oct;36(10):1512-7
references.pmid: 12243598
references.citation: JAMA. 2001 Jun 13;285(22):2864-70
references.pmid: 11401607
references.citation: Heart. 2004 Oct;90(10):1162-6
references.pmid: 15367514
references.citation: Altern Ther Health Med. 2003 Jul-Aug;9(4):50-6
references.pmid: 12868252
references.citation: Pharmacogenet Genomics. 2005 Oct;15(10):687-91
references.pmid: 16141794